Compare SMTI & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMTI | AEF |
|---|---|---|
| Founded | 1982 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.5M | 391.8M |
| IPO Year | 2008 | N/A |
| Metric | SMTI | AEF |
|---|---|---|
| Price | $34.92 | $9.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 325.8K | 79.6K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $12.48 | N/A |
| P/E Ratio | ★ N/A | $17.63 |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $6.25 |
| 52 Week High | $35.70 | $10.14 |
| Indicator | SMTI | AEF |
|---|---|---|
| Relative Strength Index (RSI) | 78.05 | 58.77 |
| Support Level | $33.99 | $8.75 |
| Resistance Level | N/A | $10.08 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | -0.26 | 0.04 |
| Stochastic Oscillator | 93.10 | 68.97 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a non-diversified closed-end, management investment company. Its investment objective is to seek to provide both current income and long-term capital appreciation. Under normal circumstances, the fund invests a majority of its net assets (plus any borrowings for investment purposes) in emerging markets (excluding China) equity securities. The performance of the fund is measured against the MSCI Emerging Markets ex-China Index. Its investment portfolio consists of equity securities from emerging market companies (excluding China), spanning multiple sectors such as Information Technology, Financials, Industrials, Consumer Discretionary, Real Estate, and others.